Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NEXYRXlHfW6ldHnvckBCe3OjeR?= NFu5VHkxNjYEoN88US=> M1\jb|I1KGh? NEWyVXN4[XSnch?= NVnjWW93dW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? MUKyOVEzOzB6Mh?=
Eca109 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PaNFAvPS9{LkWvOUDPxE1? MnP4NlQwPDhxN{KgbC=> Mnjwe4F1\XJ? M3zRSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NEL0eY8zPTF{M{C4Ni=>
Eca109 M4XR[GZ2dmO2aX;uJGF{e2G7 NX7TTZREOC53wrFOwG0> NFTDNGo3NzF{L{K0JIg> MWX3ZZRmeg>? MmTsbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= MVeyOVEzOzB6Mh?=
Eca109 MYjGeY5kfGmxbjDBd5NigQ>? NIXsWYQxNjYEoN88US=> NFewUpUzPCCq NFzXVWx4[XSnch?= NF3sWppqdmirYnn0d{Bk\WyuIHnueoF{cW:w M1rhUFI2OTJ|MEiy
Eca109 NIDO[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0ZlAvPcLizszN MkPaNlQhcA>? NGLkTVR4[XSnch?= M135eIlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> NWi1UVk3OjVzMkOwPFI>
Eca109 MWfGeY5kfGmxbjDBd5NigQ>? NHHRdGoxNjVxMTFOwG0> NH\lcY4zPCCq NUj0RlZtf2G2ZYK= Mn7G[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? NUPmW2R3OjVzMkOwPFI>
SW1116  NGLRV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzQNE42NzFxMj:1JO69VQ>? NGjNVFM1QCCq MoGzSG1UVw>? M{LrXIVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NECyd3czPDh5NEK4Oi=>
LOVO MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHBOJQxNjVxMT:yM|Uh|ryP M4PXPVQ5KGh? MVrEUXNQ NHGxNmtmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MXGyOFg4PDJ6Nh?=
SW1116  MUXGeY5kfGmxbjDBd5NigQ>? M4PIeVExKM7:TR?= NFLvN5Q1QCCq NHXiZohFVVOR NHnUU29qdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? MUmyOFg4PDJ6Nh?=
LOVO NG[1cI5HfW6ldHnvckBCe3OjeR?= NUG2WWNuOTBizszN NIPMNpk1QCCq M4f2SGROW09? MWXpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> Mn7oNlQ5PzR{OE[=
SW1116  MVLBdI9xfG:|aYOgRZN{[Xl? M4n0W|ExKM7:TR?= NWrIcWU3PDhiaB?= NWLPPVVJTE2VTx?= MV3lcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NF\vOmYzPDh5NEK4Oi=>
LOVO NW\6UIpJSXCxcITvd4l{KEG|c3H5 MoHmNVAh|ryP M3PlflQ5KGh? NGjhWJpFVVOR NIW2NGVmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NUTQWGVYOjR6N{SyPFY>
RPMI-8226 MneyRZBweHSxc3nzJGF{e2G7 MXOxM|Ih|ryP NY[xOYoxPDhxN{KvPVYhcA>? MWDEUXNQ NGPNeIdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUCxSohVOjR6M{OxNFg>
OPM-2  NULXPJFNSXCxcITvd4l{KEG|c3H5 Mn\FNU8zKM7:TR?= MknUO|IwQTZxMUKwJIg> MVHEUXNQ NXHubo5EcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXGyOFg{OzFyOB?=
JJN3  MVLBdI9xfG:|aYOgRZN{[Xl? MX:wMlUwOSEQvF2= Mki4NlQwPDhiaB?= MnrmSG1UVw>? MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHPYeZYzPDh|M{GwPC=>
NCI-H929  M{nsTGFxd3C2b4Ppd{BCe3OjeR?= M4nFXFEwOiEQvF2= MoXpO|IwQTZxMUKwJIg> NIr6WpBFVVOR NFW1S2dqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXqyOFg{OzFyOB?=
RPMI-8226 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixM|Ih|ryP M{O1VFI1NzR6L{eyJIg> NXLqUGlZTE2VTx?= MkD6ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NUPTWoc3OjR6M{OxNFg>
OPM-2  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiwNU8zKM7:TR?= Mm\KNlQwPDhxN{KgbC=> MVnEUXNQ MYXh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NYCwNpRsOjR6M{OxNFg>
JJN3  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlUwOSEQvF2= NXvlRpBnOjRxNEivO|IhcA>? MV7EUXNQ MXzh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MYOyOFg{OzFyOB?=
NCI-H929  NFroOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH2VWdPOS9{IN88US=> MVuyOE81QC95MjDo NYnRS4xXTE2VTx?= MYHh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NGj5NVgzPDh|M{GwPC=>
HeLa NVy0UHBiU2mwYYPlJGF{e2G7 NGPL[W5McT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy Ml7TNlQ4QDByOUi=
HeLa MoH4T4lv[XOnIFHzd4F6 MoTFT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy M3TH[|I1PzhyMEm4
HeLa MX;LbY5ie2ViQYPzZZk> NV;mW|B{U2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? MmOyNlQ4QDByOUi=
HeLa NVi1dGNOU2mwYYPlJGF{e2G7 NWG2TZdwU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? NH\oVFUzPDd6MEC5PC=>
NB4 MmfKSpVv[3Srb36gRZN{[Xl? MYGyMlUwPS95LkWvNVAh|ryP MYeyOEBp MkC4SG1UVw>? NYnkfGtjcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NET4Tm8zPDR6NEi3NC=>
CD4+ CD25− T  NFH5TJBHfW6ldHnvckBCe3OjeR?= MV6xM|Uh|ryP NV\G[mRvemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w NU\Q[GxkOjR2N{[zOlA>
BV-173 MYPBdI9xfG:|aYOgRZN{[Xl? NESw[VYxNjJ3L{CuOU8xNjd3L{Gg{txO MYe0PE84Oi97NjDo MYVCpHBDWw>? M2jiS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NH\BUnczPDR{M{[xNy=>
ML-1 MWfBdI9xfG:|aYOgRZN{[Xl? MUCwMlI2NzBwNT:wMlc2NzFizszN MWC0PE84Oi97NjDo Mne5xsBRSlN? NITXSJdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MnnINlQ1OjN4MUO=
HL-60 MmrqRZBweHSxc3nzJGF{e2G7 MWKwMlI2NzBwNT:wMlc2NzFizszN MnfSOFgwPzJxOU[gbC=> NEHaOIjDqFCEUx?= NELZ[o1qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NYDFVnpNOjR2MkO2NVM>
KG-1a NUPKVVVkSXCxcITvd4l{KEG|c3H5 Mkj1NE4zPS9yLkWvNE44PS9zIN88US=> NEDiR2o1QC95Mj:5OkBp NHHFNGLDqFCEUx?= NXG5TVFncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NIKwV3UzPDR{M{[xNy=>
BV-173 MoXvSpVv[3Srb36gRZN{[Xl? NXLSZlhsOjVyL{WwNI5O MXS0PEBp M2PUWOKhWEKV NGT4OlVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M{PZZ|I1PDJ|NkGz
CEM M2jURmZ2dmO2aX;uJGF{e2G7 MUCyOVAwPTBybl2= MVm0PEBp MlfmxsBRSlN? MUfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NUiyV2tHOjR2MkO2NVM>
HL-60 MYTGeY5kfGmxbjDBd5NigQ>? M3;5SlI2OC93MEDuUS=> NHLFNYI1QCCq M3PTeOKhWEKV M1T5cYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M4[zflI1PDJ|NkGz
ML-1 NEjKW|BHfW6ldHnvckBCe3OjeR?= MkHxNlUxNzVyMH7N MXi0PEBp M2PZc:KhWEKV MYLpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NF\JWZQzPDR{M{[xNy=>
DLD-1 NGPLe2hHfW6ldHnvckBCe3OjeR?= MW[yOVAwPTBybl2= Mn3wOFghcA>? M136[eKhWEKV M2rFSoRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NE\scWwzPDR{M{[xNy=>
HCT-116 NE\JTHJHfW6ldHnvckBCe3OjeR?= Mo\CNlUxNzVyMH7N Mn;lOFghcA>? M3vuXOKhWEKV NGLke5NldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MVSyOFQzOzZzMx?=
U937-A/E-9/14/18  NFzXXXpCeG:ydH;zbZMhSXO|YYm= M3HoNVAvODFxMD6xM|EwOTBizszN NFrqWIM1QCCq M{GxOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWGyNlExOjR|MEC0OVY>
HT29 NF;QbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTIZnNNPzJiaB?= MnPSTWM2OD1zNECwxtEyPzlizszN NIruXlQzPDF5MkC2NS=>
SW48 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe2enk2PzJiaB?= MUTJR|UxRTF3LkNCtVYvOiEQvF2= MnnQNlQyPzJyNkG=
HCT116 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnzUXJnPzJiaB?= NVXMdmplUUN3ME2xMlfDuTBwNDFOwG0> M3vSWlI1OTd{ME[x
HepG2 MlPZSpVv[3Srb36gRZN{[Xl? NGDuSmYxNjVxMTFOwG0> NVP1VIJWOjRiaB?= MXzEUXNQ M{C1TZVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NYDWbXhqOjRzNE[4O|Q>
LS174T NHHLOm5HfW6ldHnvckBCe3OjeR?= MljMNE42NzFizszN M1n2TVI1KGh? NXLucopvTE2VTx?= NIO3PZdt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NI\EW2UzPDF2Nki3OC=>
HepG2 M4WyZ2Fxd3C2b4Ppd{BCe3OjeR?= NVH2d441OS9zMD:xNFAh|ryP MXS3JIQ> NYPCSppPTE2VTx?= NVPZSlZvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmnsNlQyPDZ6N{S=
LS174T NUDzXYFqSXCxcITvd4l{KEG|c3H5 NYn0WXBtOS9zMD:xNFAh|ryP MmewO{Bl M3;DU2ROW09? NV63cWxwcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHTxfVYzPDF2Nki3OC=>
QBC-939 M{C5fGFxd3C2b4Ppd{BCe3OjeR?= MYGxM|ExNzFyMDFOwG0> NH;JWZM4KGR? NEPLSppFVVOR NIm3[lRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHL1S|EzPDF2Nki3OC=>
U251 MlzvRZBweHSxc3nzJGF{e2G7 NFH0WmsyNzFyL{GwNEDPxE1? M3vNc|ch\A>? M{frNWROW09? M32x[olv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEjKVlczPDF2Nki3OC=>
HL-60 NHvGbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzVbHEyKM7:TR?= NU\QfWRbPDhiaB?= NEWzclNqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MXuyOFAxODN{NB?=
MDA‑MB‑453 NIjjeFdHfW6ldHnvckBCe3OjeR?= MnLmNE4zNzFizszN NF\qeGo4OiCq Mlj2Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NXy5RlBEOjN6NESyNlg>
HCC1569 M2\vdWZ2dmO2aX;uJGF{e2G7 M4D2V|AvOi9zIN88US=> MVu3NkBp NVnpTJNl[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MmHrNlM5PDR{Mki=
BT‑474 NFXESYpHfW6ldHnvckBCe3OjeR?= Mnf6NE4zNzFizszN MUO3NkBp MXPjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MnLWNlM5PDR{Mki=
AGS MmTERZBweHSxc3nzJGF{e2G7 NHjSXFA2NzFyL{KwM|UxKM7:TR?= MnnDOFjDqGkEoB?= M2K1[mROW09? NVXSWWQ3cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MXeyN|U5Ojd6NB?=
A549 M4jKTWFxd3C2b4Ppd{BCe3OjeR?= MkfNOU8yOC9{MD:1NEDPxE1? MnfUOFjDqGkEoB?= MXrEUXNQ NFry[IVqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NEXNdIQzOzV6Mke4OC=>
AGS  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX72bVNHPS9zMD:yNE82OCEQvF2= NWi3WYt3PDkEoHlCpC=> MYjEUXNQ NUjXWXhScW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh MWeyN|U5Ojd6NB?=
Kasumi-1 MX3BdI9xfG:|aYOgRZN{[Xl? MWqwMlUh|ryP NYnmUI85PDkEoHlCpC=> MX7k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MXeyN|Q6OzN2OB?=
OCI-AML3 MlHpRZBweHSxc3nzJGF{e2G7 NVTydHY{Oi53IN88US=> MVu0POKhcMLi Mo[z[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NWXuO4YzOjN2OUOzOFg>
MV4-11 MXHBdI9xfG:|aYOgRZN{[Xl? NFm3TIUzNjVizszN MnLvOFjDqGkEoB?= MlX3[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NHjKOoMzOzR7M{O0PC=>
NK  MVnDfZRwfG:6aYT5JGF{e2G7 NGfmUG0xNjB{LUKwJO69VQ>? NUHHXnJKPSCm MV\k[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NWqxepZ3OjN|MkiwPFg>
NK  MlryRZBweHSxc3nzJGF{e2G7 MXqwMlAzNTJyIN88US=> NFvKSHI2KGR? MWTk[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> M3;r[lI{OzJ6MEi4
NK  M{jrSWZ2dmO2aX;uJGF{e2G7 NWTJXHh6OC5yMT2yNEDPxE1? MXy1JIQ> NV;henRm[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? M3vXfFI{OzJ6MEi4
MOLT4/DNR MmDhSpVv[3Srb36gRZN{[Xl? NYfxUIdTPSEQvF2= MUe0JIQ> NYDjUXR6emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M3vQU|I{ODZyNUew
Jurkat/DOX MXvGeY5kfGmxbjDBd5NigQ>? M4rDblUh|ryP MmrMOEBl NIHpPYxz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MXGyN|A3ODV5MB?=
MOLT4/DNR M1nE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHSOUDPxE1? MYK0JIQ> MVzy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NWrjTlNWOjNyNkC1O|A>
Jurkat/DOX M1XQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjwOUDPxE1? NX;PN2xDPCCm NX\E[YQzemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MVOyN|A3ODV5MB?=
ccRCC  Ml3LRZBweHSxc3nzJGF{e2G7 MkP2NE4xOS1zMN88US=> MWm3NkBp Mnm2SG1UVw>? NUH5dpZ5cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NF\WfHMzOjh{NkS2Oy=>
TNBC  NIjoZWxCeG:ydH;zbZMhSXO|YYm= MnzvNE4xOS1zMN88US=> NV3iTY5mPzJiaB?= MmnXSG1UVw>? MWDoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MoPxNlI5OjZ2Nke=
A498 Ml\BRZBweHSxc3nzJGF{e2G7 MkPLNE4xOS1zMN88US=> NELqVVM4OiCq NUfCXndpTE2VTx?= M1jHfIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> Mly1NlI5OjZ2Nke=
KIJ265T MoC0RZBweHSxc3nzJGF{e2G7 MXKwMlAyNTFyzszN M4HxOlczKGh? Mn\KSG1UVw>? M4fSeYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MUiyNlgzPjR4Nx?=
MDA-231 NWj0[FBoSXCxcITvd4l{KEG|c3H5 NID6O4wxNjBzLUGw{txO NHTheXg4OiCq Mn;USG1UVw>? MkHSbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M2rCcVIzQDJ4NE[3
BT-20 NUnibFdXSXCxcITvd4l{KEG|c3H5 NHzoZWUxNjBzLUGw{txO M2\1UFczKGh? Ml\6SG1UVw>? Mn3ibY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M{exZVIzQDJ4NE[3
U937 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfOOU0zOCEQvF2= MVSyOE81QC95MjDo NGHDSJRqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M4TuTFIzPzZ5MEKx
HL60 NFXyRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW1MVIxKM7:TR?= MmLENlQwPDhxN{KgbC=> M4nvNolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MkDHNlI4PjdyMkG=
U937 M3[3b2Fxd3C2b4Ppd{BCe3OjeR?= MXqxOUDPxE1? MlO1NlQwPDhxN{KgbC=> NVH0[3pZcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NF;hNIUzOjd4N{CyNS=>
HL60 MnSzRZBweHSxc3nzJGF{e2G7 NE\sSXQyPSEQvF2= NXjPfWltOjRxNEivO|IhcA>? M33SbYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4C2OlIzPzZ5MEKx
LS411N  NUHxNlg4SXCxcITvd4l{KEG|c3H5 MlPXNE42KM7:TR?= M1W1SVczKGh? M{jyWolv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NYHHSnp2OjJ2NkG2PVU>
MDA-MB-231 MULBdI9xfG:|aYOgRZN{[Xl? NUHT[|JsOTBizszN NF3oW2s1QCCq NHWybI5z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXGyNVg5PzZ7Nx?=
MCF-7  MWjBdI9xfG:|aYOgRZN{[Xl? MnTjNVAh|ryP MX:0PEBp NV3tWoVLemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXX0[4pEOjF6OEe2PVc>
A375 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;jVFAvPSEQvF2= Mo\iNU82NzhiZB?= NW[5c|BKcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NWDN[4cyOjF5OU[2NlI>
SKMEL1 NGPEZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\vTVAvPSEQvF2= MnnrNU82NzhiZB?= NYe0cWYycW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NI\6dGszOTd7Nk[yNi=>
SKMEL3 NUHa[lhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljsNE42KM7:TR?= NUDmdXZROS93L{ig[C=> NIj1SZRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MVWyNVc6PjZ{Mh?=
SKMEL28 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGxZ5oxNjVizszN NIq4OWwyNzVxODDk MXLpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NGHReWszOTd7Nk[yNi=>
MeWo MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7INE42KM7:TR?= MVWxM|UwQCCm M4\FWYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MVKyNVc6PjZ{Mh?=
B16 M{TDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXjSJdVOC53IN88US=> M17JNlEwPS96IHS= NHi4OJFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NVvWN|BzOjF5OU[2NlI>
Ly 1 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzhXW4zPCCq MXzJR|UxRTdwMzFOwG0> NFLjNXgzOTd5MkC0PS=>
Ly 7 NWSwW3J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xx[FI1KGh? Mnz6TWM2OD1zMD63JO69VQ>? NU\k[GJTOjF5N{KwOFk>
Su-DHL6 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jMW|I1KGh? NX\VXYhQUUN3MP-8olIxKM7:TR?= NHPHRlgzOTd5MkC0PS=>
Ly 10 M3TLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ERoQzPCCq M{DhTGlEPTExvK6yNEDPxE1? Mn3xNlE4PzJyNEm=
RIVA NU\OXGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmyOEBp NXLJdpQyUUN3MP-8olIxKM7:TR?= MYmyNVc4OjB2OR?=
Su-DHL2 M4X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ZbFI1KGh? M4PjUGlEPTExvK6yNEDPxE1? NITnS2kzOTd5MkC0PS=>
Ly 1 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfFOFghcA>? NGnoeW5KSzVyPUCuN|Qh|ryP Ml3YNlE4PzJyNEm=
Ly 7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnqUGs1QCCq MVTJR|UxRTBwMEK1JO69VQ>? M2j5R|IyPzd{MES5
Su-DHL6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\sXJM1QCCq NV3FeWltUUN3MP-8olIxKM7:TR?= NGS5eYczOTd5MkC0PS=>
Ly 10 M1XKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj4OFghcA>? MmrhTWM2OD1zLkig{txO MViyNVc4OjB2OR?=
RIVA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy0PEBp MnvoTWM2OO,:nkKwJO69VQ>? MnHENlE4PzJyNEm=
Su-DHL2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73VYI1QCCq M2jw[WlEPTB;MUeuOEDPxE1? NU\ueWZIOjF5N{KwOFk>
Ly 1 M2Psemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfVcm1xPzJiaB?= MkLyTWM2OD1yLkCxJO69VQ>? MUKyNVc4OjB2OR?=
Ly 7 NGHLT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zBZlczKGh? MXXJR|UxRTBwMEG4JO69VQ>? M1vPSFIyPzd{MES5
Su-DHL6 M4GxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3NkBp NGqxeJJKSzVyPUGuOkDPxE1? M{fWVVIyPzd{MES5
Ly 10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT0WYpOPzJiaB?= MkWzTWM2OD1zLkKg{txO NF;zR|gzOTd5MkC0PS=>
RIVA MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC0dJR[PzJiaB?= M3rObGlEPTExvK6yNEDPxE1? M1;xNVIyPzd{MES5
Su-DHL2 M3jsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ObVJxPzJiaB?= NFPS[XVKSzVyPUGxMlIh|ryP MVGyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

Related Antibodies

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID